Top Markets
Coin of the day
Odyssey Therapeutics, Inc. Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

ODTX
株式のランク #8753
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused... Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
株価
$24.55
最終同期: 2026-08-28
時価総額
$1.18B
変化(1日)
-5.50%
変化(1年)
-
US
取引 Odyssey Therapeutics, Inc. (ODTX)

カテゴリー

Odyssey Therapeutics, Inc.(ODTX)のP/S比率
2026 時点のP/S比率 TTM: 0
Odyssey Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Odyssey Therapeutics, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH